Orgalutran (Ganirelix)

Ganirelix, a GnRH antagonist, is used in assisted reproductive technology to manage ovarian response.

• Controlled ovarian hyperstimulation for IVF: suppresses premature LH surge to allow coordinated follicle development.
• Assisted reproductive technology cycles: provides precise control of ovarian response during egg retrieval protocols.
• Ovarian stimulation for egg collection: enables timing of ovulation trigger in fertility treatment cycles.

• Ganirelix binds competitively to pituitary gonadotropin‑releasing hormone (GnRH) receptors, blocking the action of endogenous GnRH. This inhibition prevents the downstream release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby averting the natural LH surge and halting premature follicular maturation. By maintaining low LH levels, clinicians can schedule the administration of exogenous gonadotropins and trigger ovulation at the optimal time during assisted reproduction protocols.

Ganirelix may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the subcutaneous injection site.
• Headache: transient mild to moderate headache.
• Nausea or abdominal discomfort: occasional gastrointestinal upset.
• Hot flashes: brief episodes of warmth and sweating.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement and fluid shift.
• Severe allergic reaction: anaphylaxis, rash, or angioedema.
• Thromboembolic events: rare clot formation.
• Severe abdominal pain: may indicate ovarian torsion or rupture.
• Elevated liver enzymes: rare hepatic involvement.

When using Orgalutran, clinicians should observe several safety measures.

• Patient selection: assess ovarian reserve and baseline hormone levels before initiating therapy.
• Monitoring: perform regular ultrasound and serum estradiol assessments to detect excessive response.
• Concomitant medications: avoid use with other GnRH agonists or antagonists without specialist guidance.
• Pregnancy considerations: discontinue before confirmed pregnancy; safety in pregnancy not established.
• Allergy: screen for hypersensitivity to ganirelix or formulation components.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ganirelix can interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

• Concurrent GnRH agonists: may counteract the antagonist effect.
• High‑dose estrogen therapy: may reduce ganirelix efficacy.
• Other fertility drugs that strongly stimulate ovaries: increase risk of OHSS.

Moderate Interactions (Monitor Closely)

• CYP450 substrates: monitor as ganirelix may affect metabolism of certain drugs.
• Anticoagulants: observe clotting parameters due to potential vascular effects.
• Vaccines: schedule appropriately to avoid overlapping immune responses.